Kigawa J - Search Results

1

Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy.

Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Cheng X, et al. Among authors: kigawa j. Cancer. 1997 Feb 1;79(3):521-7. Cancer. 1997. PMID: 9028363

2

Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.

Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Minagawa Y, et al. Among authors: kigawa j. Jpn J Cancer Res. 1994 Sep;85(9):966-71. doi: 10.1111/j.1349-7006.1994.tb02976.x. Jpn J Cancer Res. 1994. PMID: 7961127 Free PMC article.

3

Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.

Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Kigawa J, et al. Cancer. 1993 Aug 1;72(3):804-8. doi: 10.1002/1097-0142(19930801)72:3<804::aid-cncr2820720328>3.0.co;2-n. Cancer. 1993. PMID: 8334634

4

Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.

Minagawa Y, Kigawa J, Irie T, Kanamori Y, Itamochi H, Cheng X, Terakawa N. Minagawa Y, et al. Among authors: kigawa j. Jpn J Cancer Res. 1997 Dec;88(12):1218-23. doi: 10.1111/j.1349-7006.1997.tb00352.x. Jpn J Cancer Res. 1997. PMID: 9473741 Free PMC article.

5

Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer.

Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, Oishi T, Terakawa N. Kigawa J, et al. Cancer. 1998 Feb 15;82(4):697-702. doi: 10.1002/(sici)1097-0142(19980215)82:4<697::aid-cncr12>3.0.co;2-t. Cancer. 1998. PMID: 9477102

6

Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.

Kigawa J, Minagawa Y, Cheng X, Terakawa N. Kigawa J, et al. Clin Cancer Res. 1998 Jul;4(7):1737-41. Clin Cancer Res. 1998. PMID: 9676849

7

Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.

Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J, Terakawa N. Sugiyama T, et al. Among authors: kigawa j. Cancer Lett. 1998 Jun 19;128(2):211-8. doi: 10.1016/s0304-3835(98)00065-2. Cancer Lett. 1998. PMID: 9683285 Clinical Trial.

8

A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells.

Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, Takahashi M, Nakamura T, Sato K, Terakawa N. Kanamori Y, et al. Among authors: kigawa j. Eur J Cancer. 1998 Oct;34(11):1802-6. doi: 10.1016/s0959-8049(98)00199-3. Eur J Cancer. 1998. PMID: 9893672

9

Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.

Kigawa J, Takahashi M, Minagawa Y, Oishi T, Sugiyama T, Yakushiji M, Terakawa N. Kigawa J, et al. Int J Cancer. 1999 Oct 22;84(5):521-4. doi: 10.1002/(sici)1097-0215(19991022)84:5<521::aid-ijc13>3.0.co;2-x. Int J Cancer. 1999. PMID: 10502731

10

Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma.

Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S, Terakawa N. Sato S, et al. Among authors: kigawa j. Cancer. 1999 Oct 1;86(7):1307-13. Cancer. 1999. PMID: 10506718

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters